Week of November 26, 2012: Takeda Forms New Global Medical Affairs Department; UCB, NewBridge Pharmaceuticals Partner for Middle East and African Markets; and More

Takeda Pharmaceutical has established a new organization (Global Medical Affairs Japan Department) in Takeda Development Center Japan, Pharmaceutical Development Division, with appointment of its senior leadership, effective Dec. 1, 2012. Along with this, the company’s Strategic Medical Research Planning Division, currently under Takeda Development Center Japan, will be positioned under Global Medical Affairs Japan Department. Koki Nakamura has been named general manager of the new department. Read More

The biopharmaceutical company UCB has announced that Exemed Pharmaceuticals, a manufacturer of APIs, will acquire UCB’s production facility in Vapi, India. The deal includes a multiyear supply agreement between UCB and Exemed as well as the transfer of UCB Vapi’s staff of approximately 80 members to Exemed. Read More

In a separate deal, UCB and NewBridge Pharmaceuticals, a specialty therapeutics company have agreed to make UCB’s core products Cimzia (PEGylated anti-tumor necrosis factor), Vimpat (lacosamide), and Neupro (rotigotine), available in several Middle East and African countries. Under the agreement, NewBridge acquires the rights to Cimzia, Vimpat, and Neupro from the RX Group, UCB’s previous partner in the region. UCB will operate with its new partner for the region and will supply NewBridge with the three products on an exclusive basis. NewBridge will also be responsible for managing the local regulatory approval process, future commercialization, and pharmacovigilance in each of the relevant countries. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More